zurampic
grünenthal gmbh - lesinurad - hiperurykemia - preparaty przeciw zapaleniu - zurampic, w połączeniu z inhibitorem oksydazy ksantynowej jest wskazany u dorosłych w leczeniu wspomagającym hiperurykemii u pacjentów dna (z lub bez guzki), którzy nie osiągnęli cel do kwasu moczowego w surowicy z odpowiednią dawkę oksydazy ksantynowej inhibitorem sam.
aryzalera 20 mg tabletki
krka, d.d., novo mesto d.o.o. - aripiprazolum - tabletki - 20 mg
medikinet 5 mg 5 mg tabletki
medice arzneimittel puetter gmbh & co. kg - methylphenidati hydrochloridum - tabletki - 5 mg
medikinet 10 mg 10 mg tabletki
medice arzneimittel puetter gmbh & co. kg - methylphenidati hydrochloridum - tabletki - 10 mg
medikinet 20 mg 20 mg tabletki
medice arzneimittel puetter gmbh & co. kg - methylphenidati hydrochloridum - tabletki - 20 mg
dexmedetomidine ever pharma koncentrat do sporządzania roztworu do infuzji
ever valinject gmbh - dexmedetomidinum - koncentrat do sporządzania roztworu do infuzji - 100 mcg/ml
evkeeza
ultragenyx germany gmbh - evinacumab - hipercholesterolemia - Środki modyfikujące poziom lipidów - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).
sileo
orion corporation - dexmedetomidine hydrochloride - układ nerwowy, inne leki nasenne i uspokajające, leki - psy - Łagodzenie stanu lęku i strachu związanego z hałasem u psów.
humira
abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - leki immunosupresyjne - zapoznaj się z dokumentem z informacjami o produkcie.
tyenne
fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - leki immunosupresyjne - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.